Reviewed,
UniProtKB/Swiss-Prot P25445 (TNR6_HUMAN)
Last modified
January 19, 2010.
Version 138.
History...
Clusters with 100%,
90%,
50% identity |
Documents (7) |
Third-party data |
Customize display | text xml rdf/xml gff fasta |
Names and origin
| Protein names | Recommended name: Tumor necrosis factor receptor superfamily member 6 Alternative name(s): FASLG receptor Apoptosis-mediating surface antigen FAS Apo-1 antigen CD_antigen=CD95 | ||||
| Gene names |
| ||||
| Organism | Homo sapiens (Human) [Complete proteome] | ||||
| Taxonomic identifier | 9606 [NCBI] | ||||
| Taxonomic lineage | Eukaryota › Metazoa › Chordata › Craniata › Vertebrata › Euteleostomi › Mammalia › Eutheria › Euarchontoglires › Primates › Haplorrhini › Catarrhini › Hominidae › Homo |
Protein attributes
| Sequence length | 335 AA. |
| Sequence status | Complete. |
| Sequence processing | The displayed sequence is further processed into a mature form. |
| Protein existence | Evidence at protein level. |
General annotation (Comments)
| Function | Receptor for TNFSF6/FASLG. The adapter molecule FADD recruits caspase-8 to the activated receptor. The resulting death-inducing signaling complex (DISC) performs caspase-8 proteolytic activation which initiates the subsequent cascade of caspases (aspartate-specific cysteine proteases) mediating apoptosis. FAS-mediated apoptosis may have a role in the induction of peripheral tolerance, in the antigen-stimulated suicide of mature T-cells, or both. The secreted isoforms 2 to 6 block apoptosis (in vitro). Ref.4 |
| Subunit structure | Binds DAXX. Interacts with HIPK3. Part of a complex containing HIPK3 and FADD By similarity. Binds RIPK1 and FAIM2. Interacts with BRE and FEM1B. Ref.14 Ref.15 Ref.16 Ref.18 |
| Subcellular location | Isoform 1: Cell membrane; Single-pass type I membrane protein. Isoform 2: Secreted. Isoform 3: Secreted. Isoform 4: Secreted. Isoform 5: Secreted. Isoform 6: Secreted. |
| Tissue specificity | Isoform 1 and isoform 6 are expressed at equal levels in resting peripheral blood mononuclear cells. After activation there is an increase in isoform 1 and decrease in the levels of isoform 6. Ref.3 |
| Domain | Contains a death domain involved in the binding of FADD, and maybe to other cytosolic adapter proteins. |
| Involvement in disease | Defects in FAS are the cause of autoimmune lymphoproliferative syndrome type 1A (ALPS1A) [MIM:601859]; also known as Canale-Smith syndrome (CSS). ALPS is a childhood syndrome involving hemolytic anemia and thrombocytopenia with massive lymphadenopathy and splenomegaly. Ref.6 Ref.22 Ref.23 Ref.24 Ref.25 Ref.26 Ref.28 Ref.29 Ref.30 Ref.31 Ref.33 |
| Sequence similarities | Contains 1 death domain. Contains 3 TNFR-Cys repeats. |
Ontologies
Binary interactions
With | Entry | #Exp. | IntAct | Notes |
|---|---|---|---|---|
| itself | 2 | EBI-494743,EBI-494743 | ||
| CALM1 | P62158 | 3 | EBI-494743,EBI-397435 | |
| CASP8 | Q14790 | 3 | EBI-494743,EBI-78060 | |
| DAXX | Q9UER7 | 2 | EBI-494743,EBI-77321 | |
| FADD | Q13158 | 9 | EBI-494743,EBI-494804 | |
| MAP3K5 | Q99683 | 1 | EBI-494743,EBI-476263 | |
| PDCD6 | O75340 | 1 | EBI-494743,EBI-352915 | |
| Pdcd6 | P12815 | 1 | EBI-494743,EBI-309164 | From a different organism. |
| PTPN13 | Q12923 | 1 | EBI-494743,EBI-355227 | |
| SRC | P12931 | 2 | EBI-494743,EBI-621482 | |
| YES1 | P07947 | 1 | EBI-494743,EBI-515331 |
Alternative products
| This entry describes 6 isoforms produced by alternative splicing. [Align] [Select] | ||||||
| Isoform 1 (identifier: P25445-1) This isoform has been chosen as the 'canonical' sequence. All positional information in this entry refers to it. This is also the sequence that appears in the downloadable versions of the entry. | ||||||
| Isoform 2 (identifier: P25445-2) Also known as: del2; D; The sequence of this isoform differs from the canonical sequence as follows: 66-103: GERKARDCTV...KAHFSSKCRR → DVNMESSRNA...GFVFFFCQFH 104-335: Missing. | ||||||
| Note: May be produced at very low levels due to a premature stop codon in the mRNA, leading to nonsense-mediated mRNA decay. | ||||||
| Isoform 3 (identifier: P25445-3) Also known as: del3; E; The sequence of this isoform differs from the canonical sequence as follows: 66-86: GERKARDCTVNGDEPDCVPCQ → DVNMESSRNAHSPATPSAKRK 87-335: Missing. | ||||||
| Note: May be produced at very low levels due to a premature stop codon in the mRNA, leading to nonsense-mediated mRNA decay. | ||||||
| Isoform 4 (identifier: P25445-4) Also known as: B; The sequence of this isoform differs from the canonical sequence as follows: 112-149: GLEVEINCTR...CEHCDPCTKC → DVNMESSRNA...GFVFFFCQFH 150-335: Missing. | ||||||
| Note: May be produced at very low levels due to a premature stop codon in the mRNA, leading to nonsense-mediated mRNA decay. | ||||||
| Isoform 5 (identifier: P25445-5) Also known as: C; The sequence of this isoform differs from the canonical sequence as follows: 112-132: GLEVEINCTRTQNTKCRCKPN → DVNMESSRNAHSPATPSAKRK 133-335: Missing. | ||||||
| Note: May be produced at very low levels due to a premature stop codon in the mRNA, leading to nonsense-mediated mRNA decay. | ||||||
| Isoform 6 (identifier: P25445-6) Also known as: TMdel; A; The sequence of this isoform differs from the canonical sequence as follows: 169-189: Missing. |
Sequence annotation (Features)
| Feature key | Position(s) | Length | Description | Graphical view | Feature identifier | ||||||||||||||||||||
Molecule processing | |||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Signal peptide | 1 – 25 | 25 | Potential | ||||||||||||||||||||||
| Chain | 26 – 335 | 310 | Tumor necrosis factor receptor superfamily member 6 | PRO_0000034563 | |||||||||||||||||||||
Regions | |||||||||||||||||||||||||
| Topological domain | 26 – 173 | 148 | Extracellular Potential | ||||||||||||||||||||||
| Transmembrane | 174 – 190 | 17 | Potential | ||||||||||||||||||||||
| Topological domain | 191 – 335 | 145 | Cytoplasmic Potential | ||||||||||||||||||||||
| Repeat | 47 – 83 | 37 | TNFR-Cys 1 | ||||||||||||||||||||||
| Repeat | 84 – 127 | 44 | TNFR-Cys 2 | ||||||||||||||||||||||
| Repeat | 128 – 166 | 39 | TNFR-Cys 3 | ||||||||||||||||||||||
| Domain | 230 – 314 | 85 | Death | ||||||||||||||||||||||
| Region | 212 – 317 | 106 | Interaction with HIPK3 By similarity | ||||||||||||||||||||||
Amino acid modifications | |||||||||||||||||||||||||
| Modified residue | 209 | 1 | Phosphoserine Ref.19 | ||||||||||||||||||||||
| Modified residue | 214 | 1 | Phosphothreonine Ref.19 | ||||||||||||||||||||||
| Modified residue | 225 | 1 | Phosphoserine By similarity | ||||||||||||||||||||||
| Modified residue | 230 | 1 | Phosphoserine By similarity | ||||||||||||||||||||||
| Glycosylation | 118 | 1 | N-linked (GlcNAc...) Ref.20 | ||||||||||||||||||||||
| Glycosylation | 136 | 1 | N-linked (GlcNAc...) Potential | ||||||||||||||||||||||
| Disulfide bond | 59 ↔ 73 | By similarity | |||||||||||||||||||||||
| Disulfide bond | 63 ↔ 82 | By similarity | |||||||||||||||||||||||
| Disulfide bond | 85 ↔ 101 | By similarity | |||||||||||||||||||||||
| Disulfide bond | 104 ↔ 119 | By similarity | |||||||||||||||||||||||
| Disulfide bond | 107 ↔ 127 | By similarity | |||||||||||||||||||||||
| Disulfide bond | 129 ↔ 143 | By similarity | |||||||||||||||||||||||
| Disulfide bond | 146 ↔ 157 | By similarity | |||||||||||||||||||||||
| Disulfide bond | 149 ↔ 165 | By similarity | |||||||||||||||||||||||
Natural variations | |||||||||||||||||||||||||
| Alternative sequence | 66 – 103 | 38 | GERKA…SKCRR → DVNMESSRNAHSPATPSAKR KDPDLTWGGFVFFFCQFH in isoform 2. | VSP_006481 | |||||||||||||||||||||
| Alternative sequence | 66 – 86 | 21 | GERKA…CVPCQ → DVNMESSRNAHSPATPSAKR K in isoform 3. | VSP_006483 | |||||||||||||||||||||
| Alternative sequence | 87 – 335 | 249 | Missing in isoform 3. | VSP_006484 | |||||||||||||||||||||
| Alternative sequence | 104 – 335 | 232 | Missing in isoform 2. | VSP_006482 | |||||||||||||||||||||
| Alternative sequence | 112 – 149 | 38 | GLEVE…PCTKC → DVNMESSRNAHSPATPSAKR KDPDLTWGGFVFFFCQFH in isoform 4. | VSP_006485 | |||||||||||||||||||||
| Alternative sequence | 112 – 132 | 21 | GLEVE…RCKPN → DVNMESSRNAHSPATPSAKR K in isoform 5. | VSP_006487 | |||||||||||||||||||||
| Alternative sequence | 133 – 335 | 203 | Missing in isoform 5. | VSP_006488 | |||||||||||||||||||||
| Alternative sequence | 150 – 335 | 186 | Missing in isoform 4. | VSP_006486 | |||||||||||||||||||||
| Alternative sequence | 169 – 189 | 21 | Missing in isoform 6. | VSP_006489 | |||||||||||||||||||||
| Natural variant | 16 | 1 | A → T: dbSNP rs3218619. Ref.10 | VAR_020008 | |||||||||||||||||||||
| Natural variant | 25 | 1 | A → T in non-Hodgkin lymphoma; somatic mutation. Ref.27 | VAR_013416 | |||||||||||||||||||||
| Natural variant | 28 | 1 | T → A in ALPS1A; associated with autoimmune hepatitis type 2. Ref.26 | VAR_013417 | |||||||||||||||||||||
| Natural variant | 82 | 1 | C → R in ALPS1A. Ref.31 | VAR_013418 | |||||||||||||||||||||
| Natural variant | 118 | 1 | N → S in squamous cell carcinoma; burn-scar related; somatic mutation. Ref.32 | VAR_018321 | |||||||||||||||||||||
| Natural variant | 121 | 1 | R → W in ALPS1A. Ref.24 | VAR_013419 | |||||||||||||||||||||
| Natural variant | 122 | 1 | T → I: dbSNP rs3218614. Ref.10 | VAR_020009 | |||||||||||||||||||||
| Natural variant | 178 | 1 | C → R in squamous cell carcinoma; burn-scar related; somatic mutation. Ref.32 | VAR_018322 | |||||||||||||||||||||
| Natural variant | 180 | 1 | L → F in non-Hodgkin lymphoma; somatic mutation. Ref.27 | VAR_013420 | |||||||||||||||||||||
| Natural variant | 183 | 1 | P → L in non-Hodgkin lymphoma; somatic mutation. Ref.27 | VAR_013421 | |||||||||||||||||||||
| Natural variant | 184 | 1 | I → V: dbSNP rs28362322. | VAR_052347 | |||||||||||||||||||||
| Natural variant | 198 | 1 | T → I in non-Hodgkin lymphoma; somatic mutation. Ref.27 | VAR_013422 | |||||||||||||||||||||
| Natural variant | 232 | 1 | Y → C in ALPS1A. Ref.24 | VAR_013423 | |||||||||||||||||||||
| Natural variant | 241 | 1 | T → K in ALPS1A. Ref.29 | VAR_013424 | |||||||||||||||||||||
| Natural variant | 241 | 1 | T → P in ALPS1A. Ref.22 Ref.33 | VAR_013425 | |||||||||||||||||||||
| Natural variant | 250 | 1 | R → P in ALPS1A. Ref.31 | VAR_013426 | |||||||||||||||||||||
| Natural variant | 250 | 1 | R → Q in ALPS1A. Ref.29 | VAR_013427 | |||||||||||||||||||||
| Natural variant | 255 | 1 | N → D in squamous cell carcinoma; burn-scar related; somatic mutation. Ref.32 | VAR_018323 | |||||||||||||||||||||
| Natural variant | 257 | 1 | A → D in ALPS1A. Ref.25 | VAR_013428 | |||||||||||||||||||||
| Natural variant | 260 | 1 | D → G in ALPS1A. Ref.31 | VAR_013429 | |||||||||||||||||||||
| Natural variant | 260 | 1 | D → V in ALPS1A and non-Hodgkin lymphoma; somatic mutation. dbSNP rs28929498. Ref.28 Ref.33 Ref.27 | VAR_013431 | |||||||||||||||||||||
| Natural variant | 260 | 1 | D → Y in ALPS1A. Ref.23 | VAR_013430 | |||||||||||||||||||||
| Natural variant | 262 | 1 | I → S in ALPS1A. Ref.6 | VAR_058910 | |||||||||||||||||||||
| Natural variant | 264 | 1 | N → K in non-Hodgkin lymphoma; somatic mutation. Ref.27 | VAR_013432 | |||||||||||||||||||||
| Natural variant | 270 | 1 | T → I in ALPS1A. Ref.31 Ref.33 | VAR_013433 | |||||||||||||||||||||
| Natural variant | 272 | 1 | E → G in ALPS1A. Ref.30 Ref.33 | VAR_013434 | |||||||||||||||||||||
| Natural variant | 272 | 1 | E → K in non-Hodgkin lymphoma; somatic mutation. Ref.27 | VAR_013435 | |||||||||||||||||||||
| Natural variant | 278 | 1 | L → F in non-Hodgkin lymphoma; somatic mutation. Ref.27 | VAR_013436 | |||||||||||||||||||||
| Natural variant | 299 | 1 | K → N in non-Hodgkin lymphoma; somatic mutation. Ref.27 | VAR_013437 | |||||||||||||||||||||
| Natural variant | 305 | 1 | T → I: dbSNP rs3218611. Ref.10 | VAR_020942 | |||||||||||||||||||||
| Natural variant | 310 | 1 | I → S in ALPS1A. Ref.25 | VAR_013438 | |||||||||||||||||||||
Experimental info | |||||||||||||||||||||||||
| Sequence conflict | 224 | 1 | L → F in AAR08906. Ref.10 | ||||||||||||||||||||||
| Sequence conflict | 242 | 1 | L → P in CAR92543. Ref.8 | ||||||||||||||||||||||
Secondary structure | |||||||||||||||||||||||||
Helix Strand Turn | |||||||||||||||||||||||||
| Helix | 232 – 239 | 8 | |||||||||||||||||||||||
| Helix | 242 – 250 | 9 | |||||||||||||||||||||||
| Turn | 251 – 253 | 3 | |||||||||||||||||||||||
| Helix | 256 – 264 | 9 | |||||||||||||||||||||||
| Turn | 265 – 268 | 4 | |||||||||||||||||||||||
| Helix | 273 – 284 | 12 | |||||||||||||||||||||||
| Beta strand | 287 – 289 | 3 | |||||||||||||||||||||||
| Helix | 290 – 300 | 11 | |||||||||||||||||||||||
| Helix | 306 – 318 | 13 | |||||||||||||||||||||||
| Turn | 319 – 322 | 4 | |||||||||||||||||||||||
Sequences
| ||||||||||||||||||||||||||||||||||||||||||||||||
References
| « Hide 'large scale' references | |
| [1] | "The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis." Itoh N., Yonehara S., Ishii A., Yonehara M., Mizushima S., Sameshima M., Hase A., Seto Y., Nagata S. Cell 66:233-243(1991) [PubMed: 1713127] [Abstract] Cited for: NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1). |
| [2] | "Purification and molecular cloning of the APO-1 cell surface antigen, a member of the tumor necrosis factor/nerve growth factor receptor superfamily. Sequence identity with the Fas antigen." Oehm A., Behrmann I., Falk W., Pawlita M., Maier G., Klas C., Li-Weber M., Richards S., Dhein J., Trauth B.C., Ponstingl H., Krammer P.H. J. Biol. Chem. 267:10709-10715(1992) [PubMed: 1375228] [Abstract] Cited for: NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), PROTEIN SEQUENCE OF 226-240; 269-291 AND 321-335. |
| [3] | "Differential expression of human Fas mRNA species upon peripheral blood mononuclear cell activation." Liu C., Cheng J., Mountz J.D. Biochem. J. 310:957-963(1995) [PubMed: 7575433] [Abstract] Cited for: NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 2; 3; 4 AND 6), TISSUE SPECIFICITY. |
| [4] | "Three functional soluble forms of the human apoptosis-inducing Fas molecule are produced by alternative splicing." Cascino I., Fiucci G., Papoff G., Ruberti G. J. Immunol. 154:2706-2713(1995) [PubMed: 7533181] [Abstract] Cited for: NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1; 2; 3 AND 6), FUNCTION. |
| [5] | "An N-terminal domain shared by Fas/Apo-1 (CD95) soluble variants prevents cell death in vitro." Papoff G., Cascino I., Eramo A., Starace G., Lynch D.H., Ruberti G. J. Immunol. 156:4622-4630(1996) [PubMed: 8648105] [Abstract] Cited for: NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 4 AND 5). |
| [6] | "Autoimmune lymphoproliferative syndrome (ALPS) in a patient with a new germline Fas gene mutation." Del-Rey M.J., Manzanares J., Bosque A., Aguilo J.I., Gomez-Rial J., Roldan E., Serrano A., Anel A., Paz-Artal E., Allende L.M. Immunobiology 212:73-83(2007) [PubMed: 17336828] [Abstract] Cited for: NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), VARIANT ALPS1A SER-262. |
| [7] | Schaetzlein C.E., Poehlmann R., Philippsen P., Eibel H. Submitted (JUN-1995) to the EMBL/GenBank/DDBJ databases Cited for: NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 5). Tissue: Peripheral blood lymphocyte. |
| [8] | De La Calle-Martin O. Submitted (OCT-2008) to the EMBL/GenBank/DDBJ databases Cited for: NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1). |
| [9] | "Complete sequencing and characterization of 21,243 full-length human cDNAs." Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S. Sugano S.Nat. Genet. 36:40-45(2004) [PubMed: 14702039] [Abstract] Cited for: NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). |
| [10] | NIEHS SNPs program Submitted (OCT-2003) to the EMBL/GenBank/DDBJ databases Cited for: NUCLEOTIDE SEQUENCE [GENOMIC DNA], VARIANTS THR-16; ILE-122 AND ILE-305. |
| [11] | "The DNA sequence and comparative analysis of human chromosome 10." Deloukas P., Earthrowl M.E., Grafham D.V., Rubenfield M., French L., Steward C.A., Sims S.K., Jones M.C., Searle S., Scott C., Howe K., Hunt S.E., Andrews T.D., Gilbert J.G.R., Swarbreck D., Ashurst J.L., Taylor A., Battles J. Rogers J.Nature 429:375-381(2004) [PubMed: 15164054] [Abstract] Cited for: NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. |
| [12] | Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., Turner R. Venter J.C.Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases Cited for: NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. |
| [13] | "The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC)." The MGC Project Team Genome Res. 14:2121-2127(2004) [PubMed: 15489334] [Abstract] Cited for: NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). Tissue: Urinary bladder. |
| [14] | "RIP: a novel protein containing a death domain that interacts with Fas/APO-1 (CD95) in yeast and causes cell death." Stanger B.Z., Leder P., Lee T.-H., Kim E., Seed B. Cell 81:513-523(1995) [PubMed: 7538908] [Abstract] Cited for: INTERACTION WITH RIPK1. |
| [15] | "F1Aalpha, a death receptor-binding protein homologous to the Caenorhabditis elegans sex-determining protein, FEM-1, is a caspase substrate that mediates apoptosis." Chan S.-L., Tan K.-O., Zhang L., Yee K.S.Y., Ronca F., Chan M.-Y., Yu V.C. J. Biol. Chem. 274:32461-32468(1999) [PubMed: 10542291] [Abstract] Cited for: INTERACTION WITH FEM1B. |
| [16] | "LFG: an anti-apoptotic gene that provides protection from fas-mediated cell death." Somia N.V., Schmitt M.J., Vetter D.E., Van Antwerp D., Heinemann S.F., Verma I.M. Proc. Natl. Acad. Sci. U.S.A. 96:12667-12672(1999) [PubMed: 10535980] [Abstract] Cited for: INTERACTION WITH FAIM2. |
| [17] | "An unappreciated role for RNA surveillance." Hillman R.T., Green R.E., Brenner S.E. Genome Biol. 5:R8.1-R8.16(2004) [PubMed: 14759258] [Abstract] Cited for: SPLICE ISOFORM(S) THAT ARE POTENTIAL NMD TARGET(S). |
| [18] | "A death receptor-associated anti-apoptotic protein, BRE, inhibits mitochondrial apoptotic pathway." Li Q., Ching A.K.-K., Chan B.C.-L., Chow S.K.-Y., Lim P.-L., Ho T.C.-Y., Ip W.-K., Wong C.-K., Lam C.W.-K., Lee K.K.-H., Chan J.Y.-H., Chui Y.-L. J. Biol. Chem. 279:52106-52116(2004) [PubMed: 15465831] [Abstract] Cited for: INTERACTION WITH BRE. |
| [19] | "A quantitative atlas of mitotic phosphorylation." Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E., Elledge S.J., Gygi S.P. Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008) [PubMed: 18669648] [Abstract] Cited for: PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-209 AND THR-214, MASS SPECTROMETRY. |
| [20] | "Glycoproteomics analysis of human liver tissue by combination of multiple enzyme digestion and hydrazide chemistry." Chen R., Jiang X., Sun D., Han G., Wang F., Ye M., Wang L., Zou H. J. Proteome Res. 8:651-661(2009) [PubMed: 19159218] [Abstract] Cited for: GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-118, MASS SPECTROMETRY. Tissue: Liver. |
| [21] | "NMR structure and mutagenesis of the Fas (APO-1/CD95) death domain." Huang B., Eberstadt M., Olejniczak E.T., Meadows R.P., Fesik S.W. Nature 384:638-641(1996) [PubMed: 8967952] [Abstract] Cited for: STRUCTURE BY NMR OF 218-335. |
| [22] | "Dominant interfering Fas gene mutations impair apoptosis in a human autoimmune lymphoproliferative syndrome." Fisher G.H., Rosenberg F.J., Straus S.E., Dale J.K., Middleton L.A., Lin A.Y., Strober W., Lenardo M.J., Puck J.M. Cell 81:935-946(1995) [PubMed: 7540117] [Abstract] Cited for: VARIANT ALPS1A PRO-241. |
| [23] | "Fas gene mutations in the Canale-Smith syndrome, an inherited lymphoproliferative disorder associated with autoimmunity." Drappa J., Vaishnaw A.K., Sullivan K.E., Chu J.-L., Elkon K.B. N. Engl. J. Med. 335:1643-1649(1996) [PubMed: 8929361] [Abstract] Cited for: VARIANT ALPS1A TYR-260. |
| [24] | "Missense mutations in the Fas gene resulting in autoimmune lymphoproliferative syndrome: a molecular and immunological analysis." Bettinardi A., Brugnoni D., Quiros-Roldan E., Malagoli A., La Grutta S., Correra A., Notarangelo L.D. Blood 89:902-909(1997) [PubMed: 9028321] [Abstract] Cited for: VARIANTS ALPS1A TRP-121 AND CYS-232. |
| [25] | "Clincial, immunologic, and genetic features of an autoimmune lymphoproliferative syndrome associated with abnormal lymphocyte apoptosis." Sneller M.C., Wang J., Dale J.K., Strober W., Middelton L.A., Choi Y., Fleisher T.A., Lim M.S., Jaffe E.S., Puck J.M., Lenardo M.J., Straus S.E. Blood 89:1341-1348(1997) [PubMed: 9028957] [Abstract] Cited for: VARIANTS ALPS1A ASP-257 AND SER-310. |
| [26] | "Fas/Apo1 mutations and autoimmune lymphoproliferative syndrome in a patient with type 2 autoimmune hepatitis." Pensati L., Costanzo A., Ianni A., Accapezzato D., Iorio R., Natoli G., Nisini R., Almerighi C., Balsano C., Vajro P., Vegnente A., Levrero M. Gastroenterology 113:1384-1389(1997) [PubMed: 9322534] [Abstract] Cited for: VARIANT ALPS1A ALA-28. |
| [27] | "Somatic Fas mutations in non-Hodgkin's lymphoma: association with extranodal disease and autoimmunity." Groenbaek K., Straten P.T., Ralfkiaer E., Ahrenkiel V., Andersen M.K., Hansen N.E., Zeuthen J., Hou-Jensen K., Guldberg P. Blood 92:3018-3024(1998) [PubMed: 9787134] [Abstract] Cited for: VARIANTS NON-HODGKIN LYMPHOMA THR-25; PHE-180; LEU-183; ILE-198; VAL-260; LYS-264; LYS-272; PHE-278 AND ASN-299. |
| [28] | "The clinical spectrum in a large kindred with autoimmune lymphoproliferative syndrome caused by a Fas mutation that impairs lymphocyte apoptosis." Infante A.J., Britton H.A., DeNapoli T., Middelton L.A., Lenardo M.J., Jackson C.E., Wang J., Fleisher T., Straus S.E., Puck J.M. J. Pediatr. 133:629-633(1998) [PubMed: 9821419] [Abstract] Cited for: VARIANT ALPS1A VAL-260. |
| [29] | "Autoimmune lymphoproliferative syndrome with defective Fas: genotype influences penetrance." Jackson C.E., Fischer R.E., Hsu A.P., Anderson S.M., Choi Y., Wang J., Dale J.K., Fleisher T.A., Middelton L.A., Sneller M.C., Lenardo M.J., Straus S.E., Puck J.M. Am. J. Hum. Genet. 64:1002-1014(1999) [PubMed: 10090885] [Abstract] Cited for: VARIANTS ALPS1A LYS-241 AND GLN-250. |
| [30] | "Defective apoptosis due to a point mutation in the death domain of CD95 associated with autoimmune lymphoproliferative syndrome, T-cell lymphoma, and Hodgkin's disease." Peters A.M., Kohfink B., Martin H., Griesinger F., Wormann B., Gahr M., Roesler J. Exp. Hematol. 27:868-874(1999) [PubMed: 10340403] [Abstract] Cited for: VARIANT ALPS1A GLY-272. |
| [31] | "The molecular basis for apoptotic defects in patients with CD95 (Fas/Apo-1) mutations." Vaishnaw A.K., Orlinick J.R., Chu J.-L., Krammer P.H., Chao M.V., Elkon K.B. J. Clin. Invest. 103:355-363(1999) [PubMed: 9927496] [Abstract] Cited for: VARIANTS ALPS1A ARG-82; PRO-250; GLY-260 AND ILE-270. |
| [32] | "Somatic mutations of Fas (Apo-1/CD95) gene in cutaneous squamous cell carcinoma arising from a burn scar." Lee S.H., Shin M.S., Kim H.S., Park W.S., Kim S.Y., Jang J.J., Rhim K.J., Jang J., Lee H.K., Park J.Y., Oh R.R., Han S.Y., Lee J.H., Lee J.Y., Yoo N.J. J. Invest. Dermatol. 114:122-126(2000) [PubMed: 10620127] [Abstract] Cited for: VARIANTS SQUAMOUS CELL CARCINOMA SER-118; ARG-178 AND ASP-255. |
| [33] | "The development of lymphomas in families with autoimmune lymphoproliferative syndrome with germline Fas mutations and defective lymphocyte apoptosis." Straus S.E., Jaffe E.S., Puck J.M., Dale J.K., Elkon K.B., Roesen-Wolff A., Peters A.M.J., Sneller M.C., Hallahan C.W., Wang J., Fischer R.E., Jackson C.M., Lin A.Y., Baeumler C., Siegert E., Marx A., Vaishnaw A.K., Grodzicky T., Fleisher T.A., Lenardo M.J. Blood 98:194-200(2001) [PubMed: 11418480] [Abstract] Cited for: VARIANTS ALPS1A PRO-241; VAL-260; ILE-270 AND GLY-272. |
| + | Additional computationally mapped references. |
Web resources
| Autoimmune Lymphoproliferative Syndrome Database (ALPSbase) Mutations in TNFRSF6 causing ALPS type Ia |
| GeneReviews |
| NIEHS-SNPs |
Cross-references
Sequence databases | |||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| EMBL GenBank DDBJ | M67454 mRNA. Translation: AAA63174.1. X63717 mRNA. Translation: CAA45250.1. X83490 mRNA. No translation available. X83491 mRNA. No translation available. X83492 mRNA. No translation available. X83493 mRNA. No translation available. Z47993 mRNA. Translation: CAA88031.1. Z47994 mRNA. Translation: CAA88032.1. Z47995 mRNA. Translation: CAA88033.1. Z70519 mRNA. Translation: CAA94430.1. Z70520 mRNA. Translation: CAA94431.1. AY495076 mRNA. Translation: AAS76663.1. X89101 mRNA. Translation: CAA61473.1. FM246458 mRNA. Translation: CAR92543.1. AK290978 mRNA. Translation: BAF83667.1. AY450925 Genomic DNA. Translation: AAR08906.1. AL157394 Genomic DNA. Translation: CAI13871.1. AL157394 Genomic DNA. Translation: CAI13872.1. CH471066 Genomic DNA. Translation: EAW50151.1. BC012479 mRNA. Translation: AAH12479.1. | ||||||||||||||||||||||||||||||
| IPI | IPI00170811. IPI00216357. IPI00216358. IPI00216359. IPI00291314. IPI00744894. | ||||||||||||||||||||||||||||||
| PIR | A40036. I37383. I37384. S58662. | ||||||||||||||||||||||||||||||
| RefSeq | NP_000034.1. NP_690610.1. NP_690611.1. | ||||||||||||||||||||||||||||||
| UniGene | Hs.244139 | ||||||||||||||||||||||||||||||
3D structure databases | |||||||||||||||||||||||||||||||
| PDBe RCSB PDB PDBj |
| ||||||||||||||||||||||||||||||
| SMR | P25445. Positions 60-168. | ||||||||||||||||||||||||||||||
| ModBase | Search... | ||||||||||||||||||||||||||||||
Protein-protein interaction databases | |||||||||||||||||||||||||||||||
| DIP | DIP-2998N. DIP-924N. | ||||||||||||||||||||||||||||||
| IntAct | P25445. 20 interactions. | ||||||||||||||||||||||||||||||
| STRING | P25445. | ||||||||||||||||||||||||||||||
PTM databases | |||||||||||||||||||||||||||||||
| PhosphoSite | P25445. | ||||||||||||||||||||||||||||||
Proteomic databases | |||||||||||||||||||||||||||||||
| PRIDE | P25445. | ||||||||||||||||||||||||||||||
Genome annotation databases | |||||||||||||||||||||||||||||||
| Ensembl | ENST00000355740; ENSP00000347979; ENSG00000026103; Homo sapiens. [Genome view] | ||||||||||||||||||||||||||||||
| GeneID | 355. | ||||||||||||||||||||||||||||||
| KEGG | hsa:355. | ||||||||||||||||||||||||||||||
| UCSC | uc001kfr.1. human. uc001kfu.1. human. uc001kfv.1. human. uc001kfx.1. human. uc001kfy.1. human. | ||||||||||||||||||||||||||||||
Organism-specific databases | |||||||||||||||||||||||||||||||
| CTD | 355. | ||||||||||||||||||||||||||||||
| GeneCards | GC10P090741. | ||||||||||||||||||||||||||||||
| H-InvDB | HIX0009017. | ||||||||||||||||||||||||||||||
| HGNC | HGNC:11920. FAS. | ||||||||||||||||||||||||||||||
| HPA | CAB000124. | ||||||||||||||||||||||||||||||
| MIM | 134637. gene. 601859. phenotype. | ||||||||||||||||||||||||||||||
| Orphanet | 3261. Autoimmune lymphoproliferative syndrome. | ||||||||||||||||||||||||||||||
| PharmGKB | PA36613. | ||||||||||||||||||||||||||||||
| GenAtlas | Search... | ||||||||||||||||||||||||||||||
Phylogenomic databases | |||||||||||||||||||||||||||||||
| eggNOG | prNOG13680. | ||||||||||||||||||||||||||||||
| HOVERGEN | P25445. | ||||||||||||||||||||||||||||||
| PhylomeDB | P25445. | ||||||||||||||||||||||||||||||
Enzyme and pathway databases | |||||||||||||||||||||||||||||||
| Pathway_Interaction_DB | faspathway. FAS signaling pathway (CD95). hivnefpathway. HIV-1 Nef: Negative effector of Fas and TNF-alpha. | ||||||||||||||||||||||||||||||
| Reactome | REACT_578. Apoptosis. | ||||||||||||||||||||||||||||||
Gene expression databases | |||||||||||||||||||||||||||||||
| ArrayExpress | P25445. | ||||||||||||||||||||||||||||||
| Bgee | P25445. | ||||||||||||||||||||||||||||||
| CleanEx | HS_FAS. | ||||||||||||||||||||||||||||||
| Genevestigator | P25445. | ||||||||||||||||||||||||||||||
| GermOnline | ENSG00000026103. Homo sapiens. | ||||||||||||||||||||||||||||||
Family and domain databases | |||||||||||||||||||||||||||||||
| InterPro | IPR000488. Death. IPR011029. DEATH-like. IPR008063. Fas_rcpt. IPR001368. TNFR_Cys_rich_reg. [Graphical view] | ||||||||||||||||||||||||||||||
| Gene3D | G3DSA:1.10.533.10. DEATH_like. 1 hit. | ||||||||||||||||||||||||||||||
| Pfam | PF00531. Death. 1 hit. PF00020. TNFR_c6. 2 hits. [Graphical view] | ||||||||||||||||||||||||||||||
| PRINTS | PR01680. TNFACTORR6. | ||||||||||||||||||||||||||||||
| SMART | SM00005. DEATH. 1 hit. SM00208. TNFR. 3 hits. [Graphical view] | ||||||||||||||||||||||||||||||
| PROSITE | PS50017. DEATH_DOMAIN. 1 hit. PS00652. TNFR_NGFR_1. 2 hits. PS50050. TNFR_NGFR_2. 2 hits. [Graphical view] | ||||||||||||||||||||||||||||||
| ProtoNet | Search... | ||||||||||||||||||||||||||||||
Other Resources | |||||||||||||||||||||||||||||||
| NextBio | 1471. | ||||||||||||||||||||||||||||||
| PMAP-CutDB | P25445. | ||||||||||||||||||||||||||||||
| SOURCE | Search... | ||||||||||||||||||||||||||||||
Entry information
| Entry name | TNR6_HUMAN | ||||||||
| Accession | Primary (citable) accession number: P25445 Secondary accession number(s): A9UJX4 Q6SSE9 | ||||||||
| Entry history |
| ||||||||
| Entry status | Reviewed (UniProtKB/Swiss-Prot) | ||||||||
| Annotation project | HPI (Human Proteome Initiative) | ||||||||
| Disclaimer | Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. It is not in any way intended to be used as a substitute for professional medical advice, diagnosis, treatment or care. | ||||||||
Relevant documents
| Human cell differentiation molecules CD nomenclature of surface proteins of human leucocytes and list of entries |
| Human chromosome 10 Human chromosome 10: entries, gene names and cross-references to MIM |
| Human entries with polymorphisms or disease mutations List of human entries with polymorphisms or disease mutations |
| Human polymorphisms and disease mutations Index of human polymorphisms and disease mutations |
| MIM cross-references Online Mendelian Inheritance in Man (MIM) cross-references in UniProtKB/Swiss-Prot |
| PDB cross-references Index of Protein Data Bank (PDB) cross-references |
| SIMILARITY comments Index of protein domains and families |

Clusters with


